ZIPAN-25

Post-LOE

promethazine hydrochloride

Teva

ANDAINJECTIONINJECTABLE

Approved

Nov 1978

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

ZIPAN-25 (promethazine hydrochloride) by Teva is clinical pharmacology promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. First approved in 1978.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on ZIPAN-25 at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.